Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer

Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer

The prognosis of patients with metastatic colorectal cancer (mCRC) who progressed to the first and the second lines of treatment is poor. Thus, new therapeutic strategies are needed. During the last years, emerging evidence suggests that retreatment with anti-epidermal growth factor receptor (EGFR)...

Full description

Bibliographic Details
Main Authors:	Davide Ciardiello, Giulia Martini, Vincenzo Famiglietti, Stefania Napolitano, Vincenzo De Falco, Teresa Troiani, Tiziana Pia Latiano, Javier Ros, Elena Elez Fernandez, Pietro Paolo Vitiello, Evaristo Maiello, Fortunato Ciardiello, Erika Martinelli
Format:	Article
Language:	English
Published:	MDPI AG 2021-04-01
Series:	Cancers
Subjects:	rechallenge anti-EGFR monoclonal antibodies metastatic colorectal cancer
Online Access:	https://www.mdpi.com/2072-6694/13/8/1941

Similar Items

Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials
by: Davide Ciardiello, et al.
Published: (2023-04-01)

Skin Toxicity as Predictor of Survival in Refractory Patients with <i>RAS</i> Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy
by: Davide Ciardiello, et al.
Published: (2021-11-01)

Cetuximab as third‐line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild‐type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials
by: G. Martini, et al.
Published: (2023-04-01)

Correction: Ciardiello et al. Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer. <i>Cancers</i> 2021, <i>13</i>, 1941
by: Davide Ciardiello, et al.
Published: (2022-08-01)

CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients
by: Stefania Napolitano, et al.
Published: (2022-06-01)

Circulating Tumor DNA in Identifying Resistant Sub-Clones Post EGFR Blockade: Implications for EGFR Rechallenge
by: Adithya Chennamadhavuni, et al.
Published: (2022-06-01)

Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer
by: Chiara Cremolini, et al.
Published: (2023-02-01)

Anti-EGFR Reintroduction and Rechallenge in Metastatic Colorectal Cancer (mCRC): A Real-World Analysis
by: Martin S. Schulz, et al.
Published: (2022-03-01)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
by: Qingli Cui, et al.
Published: (2022-01-01)

Effectiveness of EGFR‐TKI rechallenge immediately after PD‐1 blockade failure
by: Kyoichi Kaira, et al.
Published: (2021-03-01)

Rechallenge with EGFR-TKI after failure of immunotherapy is considered an effective treatment for advanced lung adenocarcinoma patients with EGFR exon 19 deletion: a case report
by: Shubin Chen, et al.
Published: (2023-06-01)

Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial
by: Giulia Martini, et al.
Published: (2023-02-01)

Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma
by: Nobutaka Nishimura, et al.
Published: (2022-09-01)

Case report: Rechallenge with EGFR–TKIs after immunotherapy in EGFR–mutated non–small cell lung cancer with leptomeningeal metastasis
by: Chunfa Qian, et al.
Published: (2022-11-01)

REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer
by: Hiromichi Nakajima, et al.
Published: (2021-06-01)

Melanoma: BRAFi Rechallenge
by: Christoforos S. Kosmidis, et al.
Published: (2023-05-01)

Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations
by: Tomomi Masuda, et al.
Published: (2020-08-01)

Safety and efficacy of cyclin-dependent kinase inhibitor rechallenge following ribociclib-induced limiting hypertransaminasemia
by: Jesús Fuentes-Antrás, et al.
Published: (2020-12-01)

Taxane rechallenge during metastatic disease in HER-2 negative breast cancer patients: Clinical activity, tolerance and survival results
by: Manon Réda, et al.
Published: (2023-04-01)

Efficacy of taxanes rechallenge in first-line treatment of early metastatic relapse of patients with HER2-negative breast cancer previously treated with a (neo)adjuvant taxanes regimen: A multicentre retrospective observational study
by: Antoine Vasseur, et al.
Published: (2022-10-01)

Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR‐mutant NSCLC patient with acquired LMNA‐NTRK1 fusion following osimertinib resistance
by: Jiao‐Li Wang, et al.
Published: (2022-11-01)

Genomic Profiling of <i>KRAS/NRAS/BRAF/PIK3CA</i> Wild-Type Metastatic Colorectal Cancer Patients Reveals Novel Mutations in Genes Potentially Associated with Resistance to Anti-EGFR Agents
by: Anna Maria Rachiglio, et al.
Published: (2019-06-01)

PEGylated Liposomal Doxorubicin Rechallenge following Doxorubicin-induced Pancreatitis
by: Luke Ardolino, et al.
Published: (2020-12-01)

Rechallenge of voriconazole successfully tolerated after hepatic toxicity
by: O. Narumoto, et al.
Published: (2020-01-01)

Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients
by: Stefano Mariani, et al.
Published: (2022-04-01)

Successful rechallenge with avelumab in a patient with advanced Merkel cell carcinoma who presented pembrolizumab‐induced myositis
by: Clémence Bertold, et al.
Published: (2023-12-01)

Immunotherapy Resumption/Rechallenge in Melanoma Patients after Toxicity: Do We Have Another Chance?
by: Sofia España Fernandez, et al.
Published: (2023-03-01)

Mechanisms of resistance to EGFR-targeted therapies in colorectal cancer: more than just genetics
by: Christine Parseghian, et al.
Published: (2023-09-01)

The Effectiveness of Cancer Immune Checkpoint Inhibitor Retreatment and Rechallenge—A Systematic Review
by: Adrian Perdyan, et al.
Published: (2023-07-01)

Ofloxacin-ornidazole fixed-dose combination medication-induced pancreatitis with positive rechallenge
by: Nikhil Bush, et al.
Published: (2020-01-01)

Successful rechallenge with cetuximab after progression with nivolumab for recurrent cervical lymph node metastasis from carcinoma of the tongue
by: Yasuyuki Asada, et al.
Published: (2021-07-01)

Cetuximab Rechallenge and Monotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck
by: Greg Knutzen, et al.
Published: (2015-11-01)

Lobaplatin hyperthermic intraperitoneal chemotherapy plus cytoreduction and rechallenge using cetuximab for wild-type RAS peritoneal metastatic colon cancer: a case report and literature review
by: Peilin Dai, et al.
Published: (2022-02-01)

Immune Checkpoint Inhibitors-Associated Myocarditis: Diagnosis, Treatment and Current Status on Rechallenge
by: Federica Frascaro, et al.
Published: (2023-12-01)

Efficacy of NSCLC Rechallenge with Immune Checkpoint Inhibitors following Disease Progression or Relapse
by: Maria Effrosyni Livanou, et al.
Published: (2024-03-01)

Lenvatinib rechallenge in a patient with advanced thymic carcinoma: A case report
by: Yuto Terashima, et al.
Published: (2022-12-01)

Long-term Survival after Lapatinib Rechallenge in Isolated Brain Metastasis of HER2-positive Breast Cancer
by: Bülent Karagöz, et al.
Published: (2015-01-01)

The second docetaxel rechallenge for metastatic castration-resistant prostate cancer: a case report
by: Wei Ning, et al.
Published: (2023-09-01)

Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?
by: Heidar J. Albandar, et al.
Published: (2021-02-01)

Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer
by: Elif Şenocak Taşçı, et al.
Published: (2024-01-01)